The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound

被引:130
作者
Briejer, MR
Bosmans, JP
Van Daele, P
Jurzak, M
Heylen, L
Leysen, JE
Prins, NH
Schuurkes, JAJ
机构
[1] Janssen Res Fdn, Dept Gastrointestinal Pharmacol, B-2340 Beerse, Belgium
[2] Janssen Res Fdn, Dept Med Chem Synth 1, B-2340 Beerse, Belgium
[3] Janssen Res Fdn, Dept Receptor Pharmacol, B-2340 Beerse, Belgium
关键词
prucalopride; enterokinetic; 5-HT4; receptor;
D O I
10.1016/S0014-2999(01)01087-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Prucalopride is a novel enterokinetic compound and is Be first representative of the benzofuran class. We set out to establish its pharmacological profile in various receptor binding and organ bath experiments. Receptor binding data have demonstrated prucalopride's high affinity to both investigated 5-HT4 receptor isoforms, with mean pK(i) estimates of 8.60 and 8.10 for the human 5-MT4a and 5-MT4b receptor, respectively. From the 50 other binding assays investigated in this study only the human D-4 receptor (pK(i) 5.63), the mouse 5-HT3 receptor(pK(i) 5.41) and the human sigma (i) (pK(i) 5.43) have shown measurable affinity, resulting in at least 290-fold selectivity for the 5-HT4 receptor. Classical organ bath experiments were done using isolated tissues from the rat, guinea-pig and dog gastrointestinal tract, using various protocols. Prucalopride was a 5-HT4 receptor agonist in the guinea-pig colon, as it induced contractions (pEC(50) = 7.48 +/- 0.06; insensitive to a 5-HT2A or 5-HT3 receptor antagonist, but inhibited by a 5-HT4 receptor antagonist) as well as the facilitation of electrical stimulation-induced noncholinergic contractions (blocked by a 5-HT4 receptor antagonist). Furthermore, it caused relaxation of a rat oesophagus preparation (pEC(50) = 7.81 +/- 0.17), in a 5-HT4 receptor antagonist sensitive manner. Prucalopride did not cause relevant inhibition of 5-HT2A, 5-HT2B, or 5-HT3, motilin or cholecystokinin (CCK,) receptor-mediated contractions, nor nicotinic or muscarinic acetylcholine receptor-mediated contractions, up to 10 muM. It is concluded that prucalopride is a potent, selective and specific 5-HT4 receptor agonist. As it is intended for treatment of intestinal motility disorders, it is important to note that prucalopride is devoid of anti-cholinergic, anticholinesterase or nonspecific inhibitory activity and does not antagonise 5-HT2A, 5-HT2B and 5-MT3 receptors or motilin or CCK, receptors. (C) 2001 Published by Elsevier Science B.V.
引用
收藏
页码:71 / 83
页数:13
相关论文
共 43 条
[1]   DISTRIBUTION OF ACETYLCHOLINESTERASE AND BUTYRYLCHOLINESTERASE IN MYENTERIC PLEXUS AND LONGITUDINAL MUSCLE OF GUINEA-PIG INTESTINE [J].
AMBACHE, N ;
FREEMAN, MA ;
HOBBIGER, F .
BIOCHEMICAL PHARMACOLOGY, 1971, 20 (06) :1123-&
[2]   Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration [J].
Appel-Dingemanse, S ;
Lemarechal, MO ;
Kumle, A ;
Hubert, M ;
Legangneux, E .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (05) :483-491
[3]  
ARUNLAKSHANA O, 1959, BR J PHARM CHEMOTHER, V14, P45
[4]  
BAXTER GS, 1991, N-S ARCH PHARMACOL, V343, P439
[5]   FURTHER CHARACTERIZATION OF 5-HYDROXYTRYPTAMINE RECEPTORS (PUTATIVE 5-HT2B) IN RAT STOMACH FUNDUS LONGITUDINAL MUSCLE [J].
BAXTER, GS ;
MURPHY, OE ;
BLACKBURN, TP .
BRITISH JOURNAL OF PHARMACOLOGY, 1994, 112 (01) :323-331
[6]   COMBINED DOSE-RATIO ANALYSIS OF CHOLECYSTOKININ RECEPTOR ANTAGONISTS, DEVAZEPIDE, LORGLUMIDE AND LOXIGLUMIDE IN THE GUINEA-PIG GALL-BLADDER [J].
BISHOP, LA ;
GERSKOWITCH, VP ;
HULL, RAD ;
SHANKLEY, NP ;
BLACK, JW .
BRITISH JOURNAL OF PHARMACOLOGY, 1992, 106 (01) :61-66
[7]  
Bonaventure P, 2000, SYNAPSE, V36, P35, DOI 10.1002/(SICI)1098-2396(200004)36:1<35::AID-SYN4>3.0.CO
[8]  
2-Y
[9]   FUNCTIONAL EVIDENCE FOR A 5-HT2B RECEPTOR MEDIATING CONTRACTION OF LONGITUDINAL MUSCLE IN HUMAN SMALL-INTESTINE [J].
BORMAN, RA ;
BURLEIGH, DE .
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 114 (08) :1525-1527
[10]   Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans [J].
Bouras, EP ;
Camilleri, M ;
Burton, DD ;
McKinzie, S .
GUT, 1999, 44 (05) :682-686